Experts Discuss the Efficacy of the Most Recent Treatments Available for Psoriasis

In a symposium organized by Galderma Laboratories during the XXI World Congress of Dermatology, experts stated the value of vehicles and formulations as key factors associated with patients’ compliance to treatments and therapy success. Scalp psoriasis was also discussed and products and formulations presented.


BUENOS AIRES, Argentina, October 18, 2007 –  Galderma Laboratories organized the symposium "Challenging the past and shaping the future of psoriasis therapy" ,  held during the XXI World Congress of Dermatology in Buenos Aires Argentina, on October 2.  In this event, dermatology experts from different countries presented recent studies which showed highly effective outcomes of psoriasis therapies using vehicles and formulations traditionally used in the cosmetic industry: shampoos, sprays and foams. Experts also opined that the addition of other therapies such as topical medications may complement ongoing therapies like biologics. Scalp psoriasis was also discussed and experts presented a shampoo formulation containing clobetasol propionate, an advancement in the treatment of scalp psoriasis

Key Findings

Experts at the symposium opined that, the science of dermatology is increasingly recognizing the importance of the vehicle in optimizing delivery of active agents. New dermatology products include a variety of vehicles, such as sprays, shampoos, and foam. Exciting data was presented in the symposium on the efficacy and safety of these vehicles and therapeutic formulations.

An example of the data presented states that clinical trials have shown that the clobetasol spray formulation for the treatment of moderate to severe plaque psoriasis delivers significant, visible improvement in the scaling, erythema, and plaque thickening associated with the disease. Dr. Mark G. Lebwohl presented data from a in a clinical study of 120 patients with moderate to severe plaque psoriasis, 82% became clear or almost clear after 4 weeks of treatment with the spray formulation. Success was sustained in approximately 60% of the patients for an additional 4 weeks.

Another opinion leader surmised that research has shown that the most effective topical agents for psoriasis are not necessarily greasy ointments, but rather those topical agents whose use is associated with the highest rates of patient compliance. Many doctors believe that patients generally prefer less messy vehicles. Potent topical corticosteroids, when applied consistantly, may be the most efficacious and fastest-acting medications for the treatment of psoriasis.

Regarding scalp psoriasis, although topical corticosteroids have been the most widely used treatments, innovations in vehicles delivering active drug to the affected areas of the scalp are scarce. A new shampoo formulation containing clobetasol propionate, which allows for only short contact with the
corticosteroid, has been developed. Clinical trials with this newer formulation have demonstrated its safety and efficacy.

The panelists agreed that patient comfort and compliance with prescribed regimens are key factors, and must be considered as new products are developed.

 

 

 


Speakers

Galderma assembled renowned experts who delivered the talks in this symposium:

- Javier Guillermo Ubogui, MD. Major Staff Physician, Service of Dermatology, at the National Academy of Medicine and also Medical Director of Psoriahue – Interdisciplinary Medicine for the Integral Treatment of Psoriasis, both in Buenos Aires, Argentina.

- Mark G. Lebwohl, MD. Professor and Chair of the Department of Dermatology at the Mount Sinai School of Medicine in New York, New York.

- Steven R. Feldman, MD, PhD. Professor of Dermatology, Pathology, and Public Health Sciences at Wake Forest University School of Medicine in Winston-Salem, North Carolina. He also directs the Center for Dermatology Research, a health services research facility whose mission is to improve the care of patients with skin disease.

- Bruce E. Strober, MD, PhD. Assistant Professor of Medicine in the Ronald O. Perelman Department of Dermatology at the New York University (NYU) School of Medicine in New York, New York. He is also Associate Director of the Dermatopharmacology Unit and Co-Director of the Psoriasis and Psoriatic Arthritis Center at NYU Medical Center.


About Galderma

Created in 1981 as a joint venture between Nestle and L'Oreal, Galderma is one of the leading dermatology companies in the world according to recent IMS D-Class survey. With a worldwide presence in 65 countries Galderma has over 900 sales representatives dedicated to dermatology. Galderma is a fully integrated specialty pharmaceutical company with a global sales and marketing structure and worldwide product development capability. Galderma provides innovative therapeutic skincare solutions to meet the needs of dermatology patients and physicians. The company is committed to improving the health of skin with an extensive line of products that treat a range of skincare conditions including: acne, rosacea, fungal nail infections, psoriasis, seborrheic dermatitis, pigmentary disorders, non-melanoma skin cancer and photo-damage.
 
With a new research and development lab in Sophia Antipolis (France) Galderma has one of the largest R&D facilities dedicated to dermatology. Galderma is also poised to continue making significant impact on dermatology treatments with the introduction of exciting technology and products on the horizon.

 

For more information
Ketchum Argentina
Monica Finino
monica.finino@ketchum.com.ar
011-4832-7700

Dale Weiss
Galderma
+1 817-961-5186
+1 682-552-3578 (worldwide mobile)
dale.weiss@galderma.com

 

Posted: October 2007

View comments

Hide
(web4)